European Society of Cardiology Congress

Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.

Increased risk of AF by fish oil supplement was found to be prominent in low­ risk participants with healthy lifestyles.

Full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications in critically-ill patients with COVID-19.

Digital screening more than doubled the detection rate of treatment-relevant AF in both phases of eBRAVE-AF trial.

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure.

The treatment strategy led to lower risk of major adverse cardiovascular events than usual care in older patients with recent myocardial infarction.

The risk of coronary heart disease and stroke decreased by 22% for every 1 point rise in the sleep score at baseline.

Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.

Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.

Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.

Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.

Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.

Despite conflicting evidence surrounding older patient populations, investigators found no age-specific treatment effects on major cardiovascular outcomes.

Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.

Investigators find that substitute salt better protects older people with a history of stroke or high blood pressure against secondary outcomes of cardiovascular events and death.

A recent study found no benefits of immediate angiography over a delayed or selective strategy with respect to the 30-day risk of death from any cause.

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.

The direct-acting oral anticoagulant benefitted prevention of adverse clinical events, but was associated with worse major bleeding.

New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.

Current therapies focus on relief of symptoms, but there is still an unmet need to address and target the molecular defects of hypertrophic cardiomyopathy.

Manan Pareek, MD, PhD gives an overview about what is currently known about COVID-19 and cardiovascular risk.

Investigators report on a post-hoc analysis of the EMPA-REG OUTCOME trial that assesses the efficacy of the SGLT-2 inhibitor in patients with obstructive sleep apnea.

These guidelines set by ESC and EAS 2019 established treatment goals for LDL-C, non-HDL-C, and Apo-B in patients at high risk for cardiovascular disease.

The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.

Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.

The congress president shares her favorite sessions, and ideas to integrate virtual setting successes into next year's meeting.

New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.